Skip to content

Fabry Cardiomyopathy Prospective Clinical Cohort Registry Study

Fabry Cardiomyopathy Prospective Clinical Cohort Registry Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087376
Enrollment
Unknown
Registered
2024-07-25
Start date
2024-03-13
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease, FD

Interventions

Classification of gene mutations in Fabre disease:NA

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Complete genetic testing and a- Gal A activity test meets the diagnostic criteria for FD, i.e. male a- Gal A activity is reduced and genetic testing shows a pathogenic mutation, while female genetic testing shows a pathogenic mutation a- Gal A activity decreases or substrate concentration increases. 2. Complete baseline cardiac magnetic resonance imaging examination 3. Sign informed consent form

Exclusion criteria

Exclusion criteria: Patients unwilling to provide informed consent or participate in cardiac magnetic resonance imaging follow-up

Design outcomes

Primary

MeasureTime frame
Clinical data ;Cardiac magnetic resonance imaging data ;

Countries

China

Contacts

Public ContactChen Yucheng

West China Hospital of Sichuan University

chenyucheng2003@126.com+86 189 8060 2149

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026